






Prof. Ružica Maksimović

Dijagnostička vrednost magnetne rezonance srca kod miokarditisa




**Medicinski fakultet, Univerzitet u Beogradu
Centar za radiologiju, Univerzitetski Klinički centar Srbije, Beograd**

Miokard




Myocarditis



Dg & Treatment of Myocarditis: ESC Consensus 2013

Diagnostic Criteria for Suspected Myocarditis

Caforio, Pankuweit et al. Eur Heart J 2013



In the setting of clinically suspected myocarditis (Tables 3–4), CMR findings are consistent with myocardial inflammation, if at least two of the following criteria are present:

≥2 criteria

- (1) Regional or global myocardial signal intensity increase in T2-weighted oedema images^a
- (2) Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal muscle in gadolinium-enhanced T1-weighted images^b
- (3) There is at least one focal lesion with non-ischaemic regional distribution in inversion recovery-prepared gadolinium-enhanced T1-weighted images (late gadolinium enhancement)^c


A CMR study is consistent with myocyte injury and/or scar caused by myocardial inflammation if Criterion 3 is present

A repeat CMR study between 1 and 2 weeks after the initial CMR study is recommended if


- None of the criteria are present, but the onset of symptoms has been very recent and there is strong clinical evidence for myocardial inflammation
- One of the criteria is present

The presence of LV dysfunction or pericardial effusion provides additional, supportive evidence for myocarditis


T2w FS (edem)



EGE (hiperemija)



LGE (fibroza)



Miokarditis – 2 od 3 kriterijuma su pozitivna

TABLE 1 Diagnostic Tests and Potential Findings in Patients With Acute Myocarditis*

ECG, Holter, or stress test

- AV block I-III, bundle branch block, sinus arrest
- Extrasystoles
- Supraventricular tachycardia, atrial fibrillation
- Ventricular tachycardia, ventricular fibrillation, asystole
- ST-segment and T-wave changes (ST-segment elevation, T-wave inversion)
- Intraventricular conduction delay
- New Q waves
- Low voltage

Seromarkers for myocardial necrosis

- Troponin elevation
- Creatine kinase elevation

Cardiac imaging

Echocardiography/angiography

- Regional or global systolic or diastolic dysfunction, with or without LV dilatation
- Increased wall thickness
- Pericardial effusion
- Intracavitary thrombi


CMR

- Edema
- Hyperemia or capillary leak (early gadolinium enhancement)
- Irreversible injury (necrosis, scar; late gadolinium enhancement)
- Regional or global systolic or diastolic dysfunction, with or without LV dilatation
- Increased wall thickness
- Pericardial effusion
- Intracavitary thrombi

*Clinically suspected myocarditis if ≥ 1 clinical presentation and ≥ 1 diagnostic criteria from different categories, in the absence of: 1) angiographically detectable coronary artery disease (coronary stenosis $\geq 50\%$); 2) known pre-existing cardiovascular disease or extracardiac causes that could explain the syndrome (e.g., valve disease, congenital heart disease, hyperthyroidism). Suspicion is higher with higher number of fulfilled criteria. If the patient is asymptomatic, ≥ 2 diagnostic criteria should be met. Modified with permission from Caforio et al. (12).



AV = atrioventricular; CMR = cardiovascular magnetic resonance; ECG = electrocardiogram; LV = left ventricular.

Magnetic Resonance in Myocardial Inflammation



Frederik Holmvang, MD,^c
Ingrid Kindermann, MD,^g
Thias G. Friedrich, MD^{k,l,m}

Updated Lake Louise kriterijumi


| | 2018 Lake Louise Criteria | CMR Image Examples | |
|-----------------------------------|--|---|---|
| <p>Main Criteria</p> | <p>Myocardial Edema (T2-mapping or T2W images)</p> | <p>Regional or global increase of native T2</p>  | <p>Regional or global increase of T2 signal intensity</p>  |
| | <p>Non-ischemic Myocardial Injury (Abnormal T1, ECV, or LGE)</p> | <p>Regional or global increase of native T1</p>  | <p>Regional or global increase of ECV</p>  <p>or</p> <p>Regional LGE signal increase</p>  |
| <p>Supportive Criteria</p> | <p>Pericarditis (Effusion in cine images or abnormal LGE, T2, or T1)</p> | <p>Pericardial effusion</p>  | |
| | <p>Systolic LV Dysfunction (Regional or global wall motion abnormality)</p> | <p>Regional or global hypokinesis</p>  | |

Dijagnostička tačnost 95%

Case Presentation – Biopsy Positive Myocarditis








MRI







20.06.2018. godine



LV EDD **57 mm**
LV ESD **36 mm**
IVS **10 mm**
PW **10 mm**
EF 62%, EDV 159 mm, ESV 64 ml



RV EDD 24 mm
EF 58%, EDV 149 mm, ESV 63 ml











HHV6

19.09.2018. godine









Prognostic Role of Different LGE Patterns in Patients with AM and Preserved EF

Aguaro GD, JACC 2017;70(16):1977.

N – 386 pts

ITAMY – Italian Multicenter Study on Acute Myocarditis



At Risk

| | 0 | 2 | 4 | 6 | 8 | 10 |
|-----------|-----|----|----|----|---|----|
| AS LGE | 135 | 60 | 27 | 11 | 1 | 0 |
| IL LGE | 154 | 92 | 52 | 21 | 6 | 0 |
| Other-LGE | 59 | 44 | 24 | 11 | 6 | 0 |
| No-LGE | 26 | 19 | 7 | 1 | 1 | 0 |


Study Group

Period from detection of COVID 19 to CMR 103,8±63,4 (15-303 days)

Period from cardiac symptoms to CMR 63,1±62,92 (0-296 days)

N=264 patients

Age= 42,5±15,5 (18-84 years)



General Information

| | |
|-------------------|---------|
| Smoking | (7,1%) |
| Diabetes Mellitus | (2,1%) |
| Hospitalisation | (35%) |
| Oxygen therapy | (29,6%) |

Symptoms



| | |
|-------------------------|---------|
| Headache | (33,8%) |
| Chest Pain | (26,7%) |
| Palpitation | (22,6%) |
| GIT symptoms | (45,1%) |
| Fatigue | (61,9%) |
| Shortness of breath | (50,7%) |
| Loss of taste and smell | (26,7%) |
| Pneumonia | (66,2%) |

Cardiac Related Symptoms and Signs after COVID 19

| | |
|---------------------|---------|
| Palpitation | (52,1%) |
| Fatigue | (64,8%) |
| Shortness of breath | (36,6%) |
| Chest pain | (38,1%) |
| Abnormal ECG | (66,2%) |

Clinical Case

- **JA, male, 1956**
- **COVID infection 09/ 2020**
- **Hospitalized**
- **Symptoms: tachycardia, paroxysmal atrial fibrillation, shortness of breath, cough, no high temperature**
- **Treatment: Concor, Farin**
- **No previous surgery, chronic diseases, allergy**
- **Ultrasound was normal**



Patient ID 1210956710241 Examination Date 28.11.2021.

Patient Height 168 cm Patient Weight 71 kg Heart Rate 65 beats/min

Left Ventricle - Absolute

| Cardiac Function | | | Normal Range(M) (MRI) | Unit |
|-------------------------|-----|--------|--------------------------|-------|
| Ejection Fraction: | EF | 55,17 | 56.00 - 78.00 | % |
| End Diastolic Volume | EDV | 155,86 | 77.00 - 195.00 | ml |
| End Systolic Volume | ESV | 69,88 | 19.00 - 72.00 | ml |
| Stroke Volume | SV | 85,98 | 51.00 - 133.00 | ml |
| Cardiac Output: | CO | 5,59 | 2.82 - 8.82 | l/min |
| Myocardial Mass (at ED) | | 120,14 | 118.00 - 238.00 | g |
| Myocardial Mass (Avg) | | 133,24 | 118.00 - 238.00 | g |

Patient ID 1210956710241 Examination Date 28.11.2021.

Patient Height 168 cm Patient Weight 71 kg Heart Rate 65 beats/min

Right Ventricle - Absolute

| Cardiac Function | | | Normal Range(M) (MRI) | Unit |
|-------------------------|-----|--------|--------------------------|-------|
| Ejection Fraction: | EF | 62,71 | 47.00 - 74.00 | % |
| End Diastolic Volume | EDV | 132,53 | 88.00 - 227.00 | ml |
| End Systolic Volume | ESV | 49,42 | 23.00 - 103.00 | ml |
| Stroke Volume | SV | 83,11 | 52.00 - 138.00 | ml |
| Cardiac Output: | CO | 5,4 | 2.82 - 8.82 | l/min |
| Myocardial Mass (at ED) | | 0 | 30.00 - 70.00 | g |
| Myocardial Mass (Avg) | | 0 | 30.00 - 70.00 | g |

Filling and Ejection Data

| | | | |
|---------------------|---------|------|------|
| Peak Ejection Rate: | -306,15 | n.a. | ml/s |
| Peak Ejection Time | 58,58 | n.a. | ms |
| Peak Filling Rate | 258,96 | n.a. | ml/s |
| Peak Filling Time: | 827,46 | n.a. | ms |

Patient ID 1210956710241

Examination Date 28.11.2021.

Patient Height 168 cm Patient Weight 71 kg Heart Rate 65 beats/min

Left Ventricle - Normalized

| Cardiac Function | | | Normal Range(M) (MRI) | Unit |
|-------------------------|-----|-------|--------------------------|----------|
| End Diastolic Volume | EDV | 86,35 | 47.00 - 92.00 | ml/m2 |
| End Systolic Volume | ESV | 38,71 | 12.75 - 30.00 | ml/m2 |
| Stroke Volume | SV | 47,63 | 32.00 - 62.00 | ml/m2 |
| Cardiac Index | CI | 3,1 | 1.74 - 4.20 | l/min/m2 |
| Myocardial Mass (at ED) | | 66,56 | 70.00 - 113.00 | g/m2 |
| Myocardial Mass (Avg) | | 73,82 | 70.00 - 113.00 | g/m2 |

Filling and Ejection Data

Patient ID 1210956710241 Examination Date 28.11.2021.

Patient Height 168 cm Patient Weight 71 kg Heart Rate 65 beats/min


Right Ventricle - Normalized

| Cardiac Function | | | Normal Range(M) (MRI) | Unit |
|-------------------------|-----|-------|--------------------------|----------|
| End Diastolic Volume | EDV | 73,42 | 55.00 - 105.00 | ml/m2 |
| End Systolic Volume | ESV | 27,38 | 15.43 - 42.91 | ml/m2 |
| Stroke Volume | SV | 46,04 | 32.00 - 64.00 | ml/m2 |
| Cardiac Index | CI | 2,99 | 1.74 - 4.20 | l/min/m2 |
| Myocardial Mass (at ED) | | 0 | 16.00 - 36.00 | g/m2 |
| Myocardial Mass (Avg) | | 0 | 16.00 - 36.00 | g/m2 |


Filling and Ejection Data

| | | | |
|---------------------|---------|------|---------|
| Peak Ejection Rate: | -169,61 | n.a. | ml/s/m2 |
| Peak Filling Rate | 143,46 | n.a. | ml/s/m2 |



Native T1w




Postcontrast T1w



PSIR - LGE



PSIR - LGE




AR7 LGE

Perikard

Grupa 1 – Nema perikarditis (N=129-49%)


Grupa 2 – Ima perikarditis (N=135-51%)



Poruke za poneti

- **Dobra prostorna rezolucija**
- **Odlična reporducibilnost**
- **Nema štetnog zračenja**

- **Važna uloga u dijagnostici pacijenata sa suspektnim miokarditisom**
- **Uloga u izboru optimalnog terapijskog pristupa**








MR škola srca Beograd 2023



Prof. Ružica Maksimović

Dijagnostička vrednost magnetne rezonance srca kod miokarditisa



**Medicinski fakultet, Univerzitet u Beogradu
Centar za radiologiju, Univerzitetski Klinički centar Srbije, Beograd**